We are live on ! Find out more
BOLT icon

Bolt Biotherapeutics
BOLT

44 hedge funds and large institutions have $26.8M invested in Bolt Biotherapeutics in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 14 increasing their positions, 12 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 12

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.82% less ownership

Funds ownership: 3.56% → 2.73% (-0.82%)

21% less funds holding

Funds holding: 56 → 44 (-12)

30% less capital invested

Capital invested by funds: $38.5M → $26.8M (-$11.7M)

92% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 13

Holders
44
Holders Change
-12
Holders Change %
-21.43%
% of All Funds
0.71%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
1
Increased
14
Reduced
12
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NM
Newtyn Management
New York
+$754K
2
Goldman Sachs
Goldman Sachs
New York
+$371K
3
TCM
Tang Capital Management
California
+$274K
4
Millennium Management
Millennium Management
New York
+$171K
5
BCM
Bridgeway Capital Management
Texas
+$102K

Top Sellers

Rank Fund Capital Flow
1
NHAS
Novo Holdings A/S
Denmark
-$5.48M
2
SCM
Suvretta Capital Management
New York
-$3.96M
3
RCM
RA Capital Management
Massachusetts
-$789K
4
BlackRock
BlackRock
New York
-$233K
5
CCM
CAAS Capital Management
New York
-$173K
Name Holding Trade Value Shares
Change 		Change in
Stake
VC
1
Vivo Capital
California
$5.03M – – –
SI
2
Sofinnova Investments
California
$3.58M – – –
Citadel Advisors
3
Citadel Advisors
Florida
$3.58M +$164 +6 +0%
PBPIA
4
Pivotal bioVenture Partners Investment Advisor
California
$2.46M – – –
NFGH
5
Nan Fung Group Holdings
Hong Kong
$1.52M – – –
NM
6
Newtyn Management
New York
$1.5M +$754K +27,500 +92%
SB
7
Samsara BioCapital
California
$1.36M – – –
Vanguard Group
8
Vanguard Group
Pennsylvania
$1.21M -$16.4K -599 -1%
O
9
OrbiMed
New York
$1M – – –
BOTOTLSJU
10
Board of Trustees of The Leland Stanford Junior University
California
$936K – – –
Renaissance Technologies
11
Renaissance Technologies
New York
$574K +$65.3K +2,384 +12%
HCM
12
Hawkeye Capital Management
Florida
$540K – – –
TCM
13
Tang Capital Management
California
$520K +$274K +10,000 +100%
Goldman Sachs
14
Goldman Sachs
New York
$368K +$371K +13,544 +2,231%
OMC
15
Oasis Management Company
Cayman Islands
$364K – – –
BlackRock
16
BlackRock
New York
$355K -$233K -8,504 -38%
Millennium Management
17
Millennium Management
New York
$316K +$171K +6,251 +106%
Assenagon Asset Management
18
Assenagon Asset Management
Luxembourg
$294K -$74.2K -2,708 -19%
BCM
19
Bridgeway Capital Management
Texas
$244K +$102K +3,720 +66%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$200K +$16.3K +593 +8%
PFMU
21
Privium Fund Management (UK)
United Kingdom
$151K – – –
MAM
22
Marquette Asset Management
Minnesota
$127K +$46.7K +1,703 +53%
Fidelity Investments
23
Fidelity Investments
Massachusetts
$102K -$1.12K -41 -1%
State Street
24
State Street
Massachusetts
$63.4K – – –
Russell Investments Group
25
Russell Investments Group
United Kingdom
$52.3K -$34K -1,240 -38%
1
2 3

BOLT Hedge Fund Activity: Q4 2022 in Review

44 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q4 2022, worth a combined $26.8M — down 30% from $38.5M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of BOLT and 1 opened new positions — a net loss of 12 holders — while 12 trimmed existing stakes and 14 added.

The largest buyer was Newtyn Management, adding an estimated $754K. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $5.48M sold.

  • 44 institutional investors held Bolt Biotherapeutics (BOLT) as of Q4 2022, down from 56 in Q3 2022.
  • Funds reported $26.8M of Bolt Biotherapeutics stock for Q4 2022, down 30% quarter-over-quarter.
  • 1 fund opened new Bolt Biotherapeutics positions in Q4 2022 and 13 closed out, a net change of -12 holders.
  • The largest Bolt Biotherapeutics buyer in Q4 2022 was Newtyn Management, an estimated $754K added.
  • The largest Bolt Biotherapeutics seller in Q4 2022 was Novo Holdings A/S, an estimated $5.48M sold.

Based on aggregated 13F filings for Q4 2022.